2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:Ta59,Rates of physician-diagnosed eczema have been increasing among older adults, but little is known regarding the pathophysiologic processes and best treatments in this subgroup. Preliminary data suggest that medications-antihypertensive medications in particular-may contribute to eczematous dermatitis; however, there are limited population-based data on the proportion of eczematous dermatitis diagnoses among older adults that may be attributed to antihypertensive drugs. To determine whether antihypertensive drug use is associated with eczematous dermatitis in older adults. This was a longitudinal cohort study of a population-based sample of individuals 60 years and older without a diagnosis of eczematous dermatitis at baseline. It was conducted at primary care practices participating in The Health Improvement Network in the United Kingdom from January 1, 1994, to January 1, 2015. Data analyses were performed from January 6, 2020, to February 6, 2024. Exposure date by first prescription for an antihypertensive drug within each drug class. Newly active eczematous dermatitis was based on the first date for 1 of the 5 most common eczema codes used in a previously validated algorithm. Among the total study sample of 1 561 358 older adults (mean [SD] age, 67 [9] years; 54% female), the overall prevalence of eczematous dermatitis was 6.7% during a median (IQR) follow-up duration of 6 (3-11) years. Eczematous dermatitis incidence was higher among participants receiving antihypertensive drugs than those who did not (12 vs 9 of 1000 person-years of follow-up). Adjusted Cox proportional hazard models found that participants who received any antihypertensive drugs had a 29% increased hazard rate of any eczematous dermatitis (hazard ratio [HR], 1.29; 95% CI, 1.26-1.31). When assessing each antihypertensive drug class individually, the largest effect size was observed for diuretic drugs (HR, 1.21; 95% CI, 1.19-1.24) and calcium channel blockers (HR, 1.16; 95% CI, 1.14-1.18), and the smallest effect sizes were for angiotensin-converting enzyme inhibitors (HR, 1.02; 95% CI, 1.00-1.04) and β-blockers (HR, 1.04; 95% CI, 1.02-1.06). This cohort study found that antihypertensive drugs were associated with a small increased rate of eczematous dermatitis, with effect sizes largest for calcium channel blockers and diuretic drugs, and smallest for angiotensin-converting enzyme inhibitors and β-blockers. Although additional research is needed to understand the mechanisms underlying the association, these data could be helpful to clinicians to guide management when a patient presents with eczematous dermatitis in older age.31:Td10,ImportanceRates of physician-diagnosed eczema have been increasing among older adults, but little is known regarding the pathophysiologic processes and best treatments in this subgroup. Preliminary data suggest that medications—antihypertensive medications in particular—may contribute to eczematous dermatitis; however, there are limited population-based data on the proportion of eczematous dermatitis diagnoses among older adults that may be attributed to antihypertensive drugs.ObjectivesTo determine whether antihypertensive drug use is associated with eczematous dermatitis in older adults.Design, Settings, and ParticipantsThis was a longitudinal cohort study of a population-based sample of individuals 60 years and older without a diagnosis of eczematous dermatitis at baseline. It was conducted at primary care practices participating in The Health Improvement Network in the United Kingdom from January 1, 1994, to January 1, 2015. Data analyses were performed from January 6, 2020, to February 6, 2024.ExposureExposure date by first prescription for an antihypertensive drug within each drug class.Main outcome measuresNewly active eczematous dermatitis was based on the first date for 1 of the 5 most common eczema codes used in a previously validated algorithm.ResultsAmong the total study sample of 1 561 358 older adults (mean [SD] age, 67 [9] years; 54% female), the overall prevalence of eczematous dermatitis was 6.7% during a median (IQR) follow-up duration of 6 (3-11) years. Eczematous dermatitis incidence was higher among participants receiving antihypertensive drugs than those who did not (12 vs 9 of 1000 person-years of follow-up). Adjusted Cox proportional hazard models found that participants who received any antihypertensive drugs had a 29% increased hazard rate of any eczematous dermatitis (hazard ratio [HR], 1.29; 95% CI, 1.26-1.31). When assessing each antihypertensive drug class individually, the largest effect size was observed for diuretic drugs (HR, 1.21; 95% CI, 1.19-1.24) and calcium channel blockers (HR, 1.16; 95% CI, 1.14-1.18), and the smallest effect sizes were for angiotensin-converting enzyme inhibitors (HR, 1.02; 95% CI, 1.00-1.04) and β-blockers (HR, 1.04; 95% CI, 1.02-1.06).Conclusions and RelevanceThis cohort study found that antihypertensive drugs were associated with a small increased rate of eczematous dermatitis, with effect sizes largest for calcium channel blockers and diuretic drugs, and smallest for angiotensin-converting enzyme inhibitors and β-blockers. Although additional research is needed to understand the mechanisms underlying the association, these data could be helpful to clinicians to guide management when a patient presents with eczematous dermatitis in older age.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Eczematous Dermatitis: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Eczematous Dermatitis (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Eczematous%20Dermatitis\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Eczematous Dermatitis\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Eczematous%20Dermatitis\"}]}}"}}]],["$","$L2f",null,{"title":"Eczematous Dermatitis: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Eczematous Dermatitis with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1001/jamaophthalmol.2026.1241","pmid":"42096193","title":"Vitiligolike Leukoderma Associated With Chronic Unilateral Topical Ophthalmic Atropine and Dorzolamide","journal_title":"JAMA Ophthalmology","journal_issn":"2168-6165","published_at":"2026-05-07T00:00:00.000Z","url":"https://doi.org/10.1001/jamaophthalmol.2026.1241","source_score":3,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2026-05-11","doi":"10.1001/jamaophthalmol.2026.1241","days":"7","issn":"2168-6165","rank":"9","field":"Clinical Medicine","score":"3","category":"Ophthalmology","categories":["Ophthalmology"],"_categories":["Ophthalmology"]},"pubmed":{"doi":"10.1001/jamaophthalmol.2026.1241","title":"Vitiligolike Leukoderma Associated With Chronic Unilateral Topical Ophthalmic Atropine and Dorzolamide.","journal":"JAMA ophthalmology","methods":"","results":"","abstract":"This case report discusses a patient with vitiligolike hypopigmentation and eczematous dermatitis associated with topical treatment with atropine and dorzolamide.","keywords":[],"pubmed_id":"42096193","conclusions":"","publication_date":"2026-05-07T00:00:00"},"crossref":{"DOI":"10.1001/jamaophthalmol.2026.1241","URL":"https://doi.org/10.1001/jamaophthalmol.2026.1241","ISSN":["2168-6165"],"link":[{"URL":"https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2848369/jamaophthalmology_bruni_2026_lo_260003_1776890878.1191.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Vitiligolike Leukoderma Associated With Chronic Unilateral Topical Ophthalmic Atropine and Dorzolamide"],"author":[{"given":"Francesco","family":"Bruni","sequence":"first","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom"}]},{"given":"Zaid","family":"Alsafi","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom"}]},{"given":"Ali","family":"Abbas","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom"}]}],"issued":{"date-parts":[[2026,5,7]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2026-05-07T15:30:34Z","timestamp":1778167834000,"date-parts":[[2026,5,7]]},"indexed":{"date-time":"2026-05-07T16:15:33Z","timestamp":1778170533189,"date-parts":[[2026,5,7]]},"subject":[],"abstract":"This case report discusses a patient with vitiligolike hypopigmentation and eczematous dermatitis associated with topical treatment with atropine and dorzolamide.","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2848369"}},"subtitle":[],"deposited":{"date-time":"2026-05-07T15:30:34Z","timestamp":1778167834000,"date-parts":[[2026,5,7]]},"issn-type":[{"type":"print","value":"2168-6165"}],"published":{"date-parts":[[2026,5,7]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.5693/djo.02.2024.05.001","key":"elo260003r1","year":"2025","issue":"1","author":"Karimaghaei","volume":"31","first-page":"29","unstructured":null,"article-title":"Periorbital skin hypopigmentation associated with the use of topical glaucoma medications.","journal-title":"Digit J Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1089/derm.2023.0033","key":"elo260003r2","year":"2023","issue":"6","author":"Ashton","volume":"34","first-page":"480","unstructured":null,"article-title":"Contact dermatitis to ophthalmic solutions: an update.","journal-title":"Dermatitis","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamaophthalmol.2025.2656","key":"elo260003r3","year":"2025","issue":"9","author":"Viswanath","volume":"143","first-page":null,"unstructured":null,"article-title":"Periocular leukoderma associated with atropine eye drops.","journal-title":"JAMA Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaip.2015.02.009","key":"elo260003r4","year":"2015","issue":"3","author":"Fonacier","volume":"3","first-page":"S1","unstructured":null,"article-title":"Contact dermatitis: a practice parameter-update 2015.","journal-title":"J Allergy Clin Immunol Pract","doi-asserted-by":"publisher"}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Ophthalmology"],"reference-count":4,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,5,7]]},"references-count":4,"short-container-title":["JAMA Ophthalmol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamaophthalmol.2026.1241","is_oa":false,"title":"Vitiligolike Leukoderma Associated With Chronic Unilateral Topical Ophthalmic Atropine and Dorzolamide","updated":"2026-05-08T16:02:47+00:00","published_date":"2026-05-07","best_oa_location":null}},"created_at":"2026-05-12T13:18:05.194Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1001/jamaophthalmol.2026.1241","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1241","tag_type":"condition","value":"Eczematous Dermatitis","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1241","tag_type":"condition","value":"Vitiligo-Like Leukoderma","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1241","tag_type":"generic","value":"atropine","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1241","tag_type":"generic","value":"dorzolamide","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1241","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1241","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1241","tag_type":"modality","value":"Topical Anticholinergic","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1241","tag_type":"modality","value":"Topical Carbonic Anhydrase Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1241","tag_type":"sample_size","value":"n=1","value_numeric":1},{"paper_doi":"10.1001/jamaophthalmol.2026.1241","tag_type":"study_design","value":"Case Report","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1241","tag_type":"warning","value":"It is unclear whether atropine, dorzolamide, or the combination is responsible for the skin changes.","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1241","tag_type":"warning","value":"Only a single patient is described; no control, comparator, or rechallenge data are available, making causal attribution uncertain.","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.1241","tag_type":"warning","value":"The specific indication for which atropine and dorzolamide were prescribed (e.g., glaucoma, myopia control) is not stated in the abstract.","value_numeric":null}],"summaries":{"what_studied":"A case report examining vitiligolike hypopigmentation and eczematous dermatitis in a patient using chronic unilateral topical ophthalmic atropine and dorzolamide.","key_result":"The patient developed vitiligolike leukoderma and eczematous dermatitis temporally associated with long-term unilateral use of topical atropine and dorzolamide eye drops.","limitations":"Single case report limits generalizability; causality cannot be firmly established; no rechallenge or dechallenge data reported.","practice_takeaway":"Clinicians prescribing chronic topical ophthalmic atropine or dorzolamide should be aware of the potential for periocular or eyelid hypopigmentation and dermatitis. Unexplained vitiligolike skin changes near the eye in patients on these drops warrant dermatologic evaluation."}},{"doi":"10.1001/jamadermatol.2024.1230","pmid":"38776099","title":"Antihypertensive Medications and Eczematous Dermatitis in Older Adults","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2024-05-22T00:00:00.000Z","url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11112493","source_score":71,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2024-05-30","doi":"10.1001/jamadermatol.2024.1230","days":"30","issn":"2168-6068","rank":"5","field":"Clinical Medicine","score":"71","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2024.1230","title":"Antihypertensive Medications and Eczematous Dermatitis in Older Adults.","journal":"JAMA dermatology","methods":"","results":"Among the total study sample of 1 561 358 older adults (mean [SD] age, 67 [9] years; 54% female), the overall prevalence of eczematous dermatitis was 6.7% during a median (IQR) follow-up duration of 6 (3-11) years. Eczematous dermatitis incidence was higher among participants receiving antihypertensive drugs than those who did not (12 vs 9 of 1000 person-years of follow-up). Adjusted Cox proportional hazard models found that participants who received any antihypertensive drugs had a 29% increased hazard rate of any eczematous dermatitis (hazard ratio [HR], 1.29; 95% CI, 1.26-1.31). When assessing each antihypertensive drug class individually, the largest effect size was observed for diuretic drugs (HR, 1.21; 95% CI, 1.19-1.24) and calcium channel blockers (HR, 1.16; 95% CI, 1.14-1.18), and the smallest effect sizes were for angiotensin-converting enzyme inhibitors (HR, 1.02; 95% CI, 1.00-1.04) and β-blockers (HR, 1.04; 95% CI, 1.02-1.06).","abstract":"$30","keywords":[],"pubmed_id":"38776099","conclusions":"","publication_date":"2024-05-22T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2024.1230","URL":"https://doi.org/10.1001/jamadermatol.2024.1230","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2819258/jamadermatology_ye_2024_oi_240013_1721149710.57994.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"710","type":"journal-article","issue":"7","score":1,"title":["Antihypertensive Medications and Eczematous Dermatitis in Older Adults"],"author":[{"given":"Morgan","family":"Ye","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}]},{"given":"Leslie N.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}]},{"given":"Ian","family":"Douglas","sequence":"additional","affiliation":[{"name":"Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom"}]},{"given":"David J.","family":"Margolis","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"}]},{"given":"Sinéad M.","family":"Langan","sequence":"additional","affiliation":[{"name":"Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom"}]},{"given":"Katrina","family":"Abuabara","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"},{"name":"Division of Epidemiology and Biostatistics, University of California, Berkeley"}]}],"issued":{"date-parts":[[2024,7,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"160","created":{"date-time":"2024-05-22T15:33:01Z","timestamp":1716391981000,"date-parts":[[2024,5,22]]},"indexed":{"date-time":"2025-07-15T03:25:04Z","timestamp":1752549904875,"date-parts":[[2025,7,15]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2819258"}},"subtitle":[],"deposited":{"date-time":"2024-07-17T15:03:22Z","timestamp":1721228602000,"date-parts":[[2024,7,17]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2024,7,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1371/journal.pone.0258219","key":"doi240013r1","year":"2021","issue":"10","author":"Chan","volume":"16","first-page":null,"unstructured":null,"article-title":"The epidemiology of atopic dermatitis in older adults: a population-based study in the United Kingdom.","journal-title":"PLoS One","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2020.2940","key":"doi240013r2","year":"2020","issue":"11","author":"Lam","volume":"156","first-page":"1240","unstructured":null,"article-title":"Inclusion of older adults in randomized clinical trials for systemic medications for atopic dermatitis: a systematic review.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240013r3","year":"2002","issue":"1 Pt 1","author":"Morin","volume":"129","first-page":"19","unstructured":null,"article-title":"Chronic eczematiform eruption in the elderly.","journal-title":"Ann Dermatol Venereol","doi-asserted-by":null},{"DOI":"10.3109/08923973.2013.797992","key":"doi240013r4","year":"2013","issue":"3","author":"Vena","volume":"35","first-page":"447","unstructured":null,"article-title":"Eczematous reactions due to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.","journal-title":"Immunopharmacol Immunotoxicol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2013.282023","key":"doi240013r5","year":"2013","issue":"22","author":"Berger","volume":"310","first-page":"2443","unstructured":null,"article-title":"Pruritus in the older patient: a clinical review.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.sder.2011.04.002","key":"doi240013r6","year":"2011","issue":"2","author":"Berger","volume":"30","first-page":"113","unstructured":null,"article-title":"Pruritus in elderly patients–eruptions of senescence.","journal-title":"Semin Cutan Med Surg","doi-asserted-by":"publisher"},{"DOI":"10.1111/cod.v86.3","key":"doi240013r8","year":"2022","issue":"3","author":"de Groot","volume":"86","first-page":"145","unstructured":null,"article-title":"Systemic allergic dermatitis (systemic contact dermatitis) from pharmaceutical drugs: A review.","journal-title":"Contact Dermatitis","doi-asserted-by":"publisher"},{"DOI":"10.1038/sj.jid.5701018","key":"doi240013r9","year":"2007","issue":"12","author":"Joly","volume":"127","first-page":"2766","unstructured":null,"article-title":"Chronic eczematous eruptions of the elderly are associated with chronic exposure to calcium channel blockers: results from a case-control study.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2013.511","key":"doi240013r10","year":"2013","issue":"7","author":"Summers","volume":"149","first-page":"814","unstructured":null,"article-title":"Chronic eczematous eruptions in the aging: further support for an association with exposure to calcium channel blockers.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2017.03.029","key":"doi240013r11","year":"2017","issue":"8","author":"Abuabara","volume":"137","first-page":"1655","unstructured":null,"article-title":"Development and validation of an algorithm to accurately identify atopic eczema patients in primary care electronic health records from the UK.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1371/journal.pone.0199026","key":"doi240013r12","year":"2018","issue":"6","author":"Pujades-Rodriguez","volume":"13","first-page":null,"unstructured":null,"article-title":"The diagnosis, burden and prognosis of dementia: A record-linkage cohort study in England.","journal-title":"PLoS One","doi-asserted-by":"publisher"},{"DOI":"10.14236/jhi.v19i4.820","key":"doi240013r13","year":"2011","issue":"4","author":"Blak","volume":"19","first-page":"251","unstructured":null,"article-title":"Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates.","journal-title":"Inform Prim Care","doi-asserted-by":"publisher"},{"DOI":"10.3399/bjgp10X483562","key":"doi240013r14","year":"2010","issue":"572","author":"Khan","volume":"60","first-page":"e128","unstructured":null,"article-title":"Validity of diagnostic coding within the General Practice Research Database: a systematic review.","journal-title":"Br J Gen Pract","doi-asserted-by":"publisher"},{"DOI":"10.1002/pds.v16:4","key":"doi240013r15","year":"2007","issue":"4","author":"Lewis","volume":"16","first-page":"393","unstructured":null,"article-title":"Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research.","journal-title":"Pharmacoepidemiol Drug Saf","doi-asserted-by":"publisher"},{"DOI":"10.1111/all.2017.72.issue-7","key":"doi240013r17","year":"2017","issue":"7","author":"Hsu","volume":"72","first-page":"1091","unstructured":null,"article-title":"Validation of International Classification of Diseases, Ninth Revision, codes for atopic dermatitis.","journal-title":"Allergy","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj.300.6732.1092","key":"doi240013r18","year":"1990","issue":"6732","author":"Chisholm","volume":"300","first-page":"1092","unstructured":null,"article-title":"The Read clinical classification.","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.v185.4","key":"doi240013r19","year":"2021","issue":"4","author":"Wan","volume":"185","first-page":"693","unstructured":null,"article-title":"Growing evidence for an association between inflammatory skin disease and chronic kidney disease.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.2018.21554","key":"doi240013r21","year":"2019","issue":"6","author":"Haneuse","volume":"321","first-page":"602","unstructured":null,"article-title":"Using the E-value to assess the potential effect of unmeasured confounding in observational studies.","journal-title":"JAMA","doi-asserted-by":"publisher"},{"DOI":"10.7326/M16-2607","key":"doi240013r22","year":"2017","issue":"4","author":"VanderWeele","volume":"167","first-page":"268","unstructured":null,"article-title":"Sensitivity analysis in observational research: introducing the E-value.","journal-title":"Ann Intern Med","doi-asserted-by":"publisher"},{"DOI":"10.1080/01621459.1999.10474144","key":"doi240013r23","year":"1999","issue":"446","author":"Fine","volume":"94","first-page":"496","unstructured":null,"article-title":"A proportional hazards model for the subdistribution of a competing risk.","journal-title":"J Am Stat Assoc","doi-asserted-by":"publisher"},{"DOI":"10.1111/cod.2017.77.issue-5","key":"doi240013r25","year":"2017","issue":"5","author":"Yoo","volume":"77","first-page":"339","unstructured":null,"article-title":"Intractable pruritus with chronic eczema in an elderly patient caused by long-term intake of calcium channel blocker.","journal-title":"Contact Dermatitis","doi-asserted-by":"publisher"},{"DOI":null,"key":"doi240013r26","year":"2002","issue":"8-9","author":"Touraud","volume":"129","first-page":"1033","unstructured":null,"article-title":"Cross-sensitivity between angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonist.","journal-title":"Ann Dermatol Venereol","doi-asserted-by":null},{"DOI":"10.1111/bjd.v186.2","key":"doi240013r27","year":"2022","issue":"2","author":"Yousaf","volume":"186","first-page":"227","unstructured":null,"article-title":"Association between atopic dermatitis and hypertension: a systematic review and meta-analysis.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1161/HYP.0000000000000047","key":"doi240013r28","year":"2016","issue":"3","author":"Elijovich","volume":"68","first-page":"e7","unstructured":null,"article-title":"Salt sensitivity of blood pressure: a scientific statement from the American Heart Association.","journal-title":"Hypertension","doi-asserted-by":"publisher"},{"DOI":"10.1126/scitranslmed.aau0683","key":"doi240013r29","year":"2019","issue":"480","author":"Matthias","volume":"11","first-page":null,"unstructured":null,"article-title":"Sodium chloride is an ionic checkpoint for human TH2 cells and shapes the atopic skin microenvironment.","journal-title":"Sci Transl Med","doi-asserted-by":"publisher"},{"DOI":"10.1093/pubmed/fdt116","key":"doi240013r30","year":"2014","issue":"4","author":"Mathur","volume":"36","first-page":"684","unstructured":null,"article-title":"Completeness and usability of ethnicity data in UK-based primary care and hospital databases.","journal-title":"J Public Health (Oxf)","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2013.10.010","key":"doi240013r32","year":"2014","issue":"2","author":"Eichenfield","volume":"70","first-page":"338","unstructured":null,"article-title":"Guidelines of care for the management of atopic dermatitis: diagnosis and assessment of atopic dermatitis.","journal-title":"J Am Acad Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/978-981-10-5541-6_18","key":"doi240013r7","year":"2018","issue":null,"author":"Tanei","volume":null,"first-page":"229","unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":null,"key":"doi240013r16","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"The Health Improvement Network (THIN). THIN database. Accessed April 17, 2024. https://www.the-health-improvement-network.com/","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi240013r20","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"UK National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. https://www.nice.org.uk/guidance/ng136","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi240013r24","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"UK National Office of Statistics. Ethnic group by age and sex, England and Wales: Census 2021. Accessed April 16, 2024. https://www.ons.gov.uk/peoplepopulationandcommunity/culturalidentity/ethnicity/articles/ethnicgroupbyageandsexenglandandwales/census2021","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"doi240013r31","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"UK National Institute for Health and Care Excellence. Starting Hypertensive Drug Treatment. Accessed November 11, 2022. https://www.nice.org.uk/guidance/ng136/chapter/Recommendations#starting-antihypertensive-drug-treatment","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"published-print":{"date-parts":[[2024,7,1]]},"reference-count":32,"published-online":null,"references-count":32,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":7},"unpaywall":{"doi":"10.1001/jamadermatol.2024.1230","is_oa":true,"title":"Antihypertensive Medications and Eczematous Dermatitis in Older Adults","updated":"2025-07-30T00:59:52+00:00","published_date":"2024-05-22","best_oa_location":{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11112493","pmh_id":"oai:pubmedcentral.nih.gov:11112493","url_for_pdf":null,"url_for_landing_page":"https://www.ncbi.nlm.nih.gov/pmc/articles/11112493"}}},"created_at":"2025-09-20T08:18:50.356Z","updated_at":"2025-09-20T08:25:17.195Z","tags":[{"paper_doi":"10.1001/jamadermatol.2024.1230","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.1230","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.1230","tag_type":"condition","value":"Eczematous Dermatitis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.1230","tag_type":"condition","value":"Hypertension","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.1230","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.1230","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.1230","tag_type":"modality","value":"Antihypertensive","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.1230","tag_type":"sample_size","value":"n=1,561,358","value_numeric":1561358},{"paper_doi":"10.1001/jamadermatol.2024.1230","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.1230","tag_type":"study_design","value":"Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2024.1230","tag_type":"warning","value":"Age group tag approximated; the cohort included adults aged 60+, not exclusively 65+.","value_numeric":null}],"summaries":{"what_studied":"A longitudinal cohort of 1,561,358 UK adults aged 60 years and older without baseline eczematous dermatitis examined whether starting antihypertensive drugs (by class) was associated with incident eczematous dermatitis during 1994–2015, with median follow-up of 6 years.","key_result":"Incidence was 12 vs 9 per 1000 person-years among antihypertensive users vs nonusers; any antihypertensive was associated with an adjusted HR 1.29 (95% CI, 1.26–1.31). By class, diuretics HR 1.21 (1.19–1.24) and calcium channel blockers 1.16 (1.14–1.18) showed the largest associations; ACE inhibitors 1.02 (1.00–1.04) and β-blockers 1.04 (1.02–1.06) the smallest.","practice_takeaway":"In older adults with new-onset eczematous dermatitis, review antihypertensive drugs as possible contributors, particularly diuretics and calcium channel blockers; the absolute excess risk was about 3 cases per 1000 person-years."}}],"initialOffset":2,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Eczematous Dermatitis"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Eczematous Dermatitis"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Eczematous Dermatitis"}}}]]

Papers